Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE We also applied CTM to construct a novel ECL immunosensor and achieve the sensitive detection of the proprotein convertase subtilisin/kexin type 9 (PCSK9), a biomarker related to cardiovascular diseases (CVDs). 31794188 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases. 31419281 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease. 30786741 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE A published Markov model was adopted to investigate lifetime outcomes: (1) number of recurrent CVD events prevented, (2) quality-adjusted life-years (QALYs) gained, (3) costs and (4) incremental cost-effectiveness ratios (ICERs) of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and ezetimibe added to statin therapy. 31243736 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in patients for primary and/or secondary prevention of cardiovascular diseases or with hypercholesterolaemia/hyperlipidaemia. 30842207 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE High PCSK9 concentrations are associated with an increased risk of cardiovascular disease (CVD). 31002780 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review. 31832834 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE There is no available evidence on the efficacy and safety of PCSK9 inhibitors in non-cardiovascular diseases, particularly cancer. 31110520 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE In patients at high cardiovascular disease risk, PCSK9 and Lp(a) are positively and dose-dependently correlated with atorvastatin dosage, whereas the presence of T2D is associated with higher PCSK9 but lower Lp(a) levels. 29103916 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE LDL cholesterol (LDL-C) lowering drugs that operate through the inhibition of PCSK9 are being pursued for the management of hypercholesterolemia and reducing its associated atherosclerotic cardiovascular disease (CVD) risk. 30448414 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Hence, design an effective method to detect serum PCSK9 is meaningful for the prevention, monitor and diagnosis of cardiovascular diseases. 31513960 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 GeneticVariation group BEFREE LDLR and PCSK9 polymorphisms have been associated with higher lipid levels and risk of cardiovascular diseases. 31441123 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Here we review the history of PCSK9 and rationale behind developing inhibitors for CVD. 30914377 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 GeneticVariation group BEFREE Different therapies have been suggested and some are used to treat elevated lipoprotein(a) levels such as niacin, PCSK9 inhibitors, and CETP inhibitors; however, to date, no randomized controlled trial has demonstrated that lowering of lipoprotein(a) leads to lower risk of cardiovascular disease. 31111240 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 GeneticVariation group GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Therefore, PCSK9 inhibition could exert beneficial effects on cardiovascular disease outcomes. 30551367 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 GeneticVariation group BEFREE Although PCSK9 inhibitors were shown to reduce the risk of cardiovascular disease, a warning was issued concerning their possible impact on cognitive functions. 31437157 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 AlteredExpression group BEFREE PCSK9 inhibitors potently lower plasma LDL-C levels in T2DM patients and reduce risk for the development of cardiovascular disease. 31002456 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE PCSK9 regulates LDL receptor degradation and plays key roles in hypercholesterolemia and related cardiovascular diseases. 31593224 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study. 30709868 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 GeneticVariation group BEFREE Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently, only 5-10% of high-risk cardiovascular patients reach the target values recommended by international guidelines. 31818446 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 AlteredExpression group BEFREE PCSK-9 levels were higher in statin users and patients with a history of cardiovascular disease. 30921469 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE We report the case of a 41-year-old woman with familial hypercholesterolaemia and premature cardiovascular disease, who was non-responsive to the action of PCSK9 inhibitor solely due to the incorrect subcutaneous injection technique. 29685715 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 GeneticVariation group BEFREE Characteristics associated with a higher CVD risk may inform the decision to initiate PCSK9 inhibition. 30746585 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.200 Biomarker group BEFREE <i>Gold standard</i> therapy with statins and the more recently developed <i>proprotein convertase subtilisin/kexin type 9</i> (PCSK9) inhibitors have improved health conditions among CVD patients by lowering <i>low density lipoprotein</i> (LDL) cholesterol. 31191301 2019